These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 39404996)

  • 1. Efficacy and Safety of Advanced Therapies in Moderately-to-Severely Active Ulcerative Colitis: a Systematic Review and Network Meta-analysis.
    Dignass A; Ainsworth C; Hartz S; Dunnewind N; Redondo I; Sapin C; Kroep S; Halfpenny N; Arcà E; Hoque S
    Adv Ther; 2024 Dec; 41(12):4446-4462. PubMed ID: 39404996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of mirikizumab compared with currently approved biologic drugs for the treatment of ulcerative colitis: A systematic review and network meta-analysis.
    Moćko P; Koperny M; Śladowska K; Holko P; Kowalska-Bobko I; Kawalec P
    Pharmacotherapy; 2024 Oct; 44(10):811-821. PubMed ID: 39320112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy of advanced treatments in biologic-naïve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis.
    Lu X; Jarrett J; Sadler S; Tan M; Dennis J; Jairath V
    Int J Clin Pharm; 2023 Apr; 45(2):330-341. PubMed ID: 36484968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis.
    Vickers AD; Ainsworth C; Mody R; Bergman A; Ling CS; Medjedovic J; Smyth M
    PLoS One; 2016; 11(10):e0165435. PubMed ID: 27776175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the economics of biologic and small molecule therapies for the treatment of moderate to severe ulcerative colitis in Japan: a cost per responder analysis of upadacitinib.
    Saruta M; Kawaguchi I; Ogawa Y; Sanchez Gonzalez Y; Numajiri N; Tang X; Miller R
    J Med Econ; 2024; 27(1):566-574. PubMed ID: 38512101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
    Rubin DT; Dotan I; DuVall A; Bouhnik Y; Radford-Smith G; Higgins PDR; Mishkin DS; Arrisi P; Scalori A; Oh YS; Tole S; Chai A; Chamberlain-James K; Lacey S; McBride J; Panés J;
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):17-27. PubMed ID: 34798036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The comparative efficacy and safety of biologics and small molecules for treating patients with ulcerative colitis in Portugal: a systematic literature review and network meta-analysis.
    Sanchez Gonzalez Y; Prata R; Alves D
    Eur Rev Med Pharmacol Sci; 2023 Jul; 27(14):6744-6759. PubMed ID: 37522686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Advanced Therapies for Moderately to Severely Active Ulcerative Colitis at Induction and Maintenance: An Indirect Treatment Comparison Using Bayesian Network Meta-analysis.
    Panaccione R; Collins EB; Melmed GY; Vermeire S; Danese S; Higgins PDR; Kwon CS; Zhou W; Ilo D; Sharma D; Sanchez Gonzalez Y; Wang ST
    Crohns Colitis 360; 2023 Apr; 5(2):otad009. PubMed ID: 36998249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
    Danese S; Vermeire S; Zhou W; Pangan AL; Siffledeen J; Greenbloom S; Hébuterne X; D'Haens G; Nakase H; Panés J; Higgins PDR; Juillerat P; Lindsay JO; Loftus EV; Sandborn WJ; Reinisch W; Chen MH; Sanchez Gonzalez Y; Huang B; Xie W; Liu J; Weinreich MA; Panaccione R
    Lancet; 2022 Jun; 399(10341):2113-2128. PubMed ID: 35644166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mirikizumab: A New Therapeutic Option for the Treatment of Ulcerative Colitis.
    Choi D; Sheridan H; Bhat S
    Ann Pharmacother; 2024 Nov; 58(11):1134-1139. PubMed ID: 38344998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.
    Lasa JS; Olivera PA; Danese S; Peyrin-Biroulet L
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):161-170. PubMed ID: 34856198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of ustekinumab vs. advanced therapies for the treatment of moderately to severely active ulcerative colitis: a systematic review and network meta-analysis.
    Welty M; Mesana L; Padhiar A; Naessens D; Diels J; van Sanden S; Pacou M
    Curr Med Res Opin; 2020 Apr; 36(4):595-606. PubMed ID: 31960724
    [No Abstract]   [Full Text] [Related]  

  • 15. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety Profile of Biologic Drugs in the Therapy of Ulcerative Colitis: A Systematic Review and Network Meta-Analysis.
    Moćko P; Kawalec P; Pilc A
    Pharmacotherapy; 2016 Aug; 36(8):870-9. PubMed ID: 27312826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative maintenance performance of all biologic agents and small molecules in ulcerative colitis: a network meta-analysis.
    Rokkas T; Gisbert JP; Ekmektzoglou K; Dassopoulos T; Niv Y; O'Morain C
    Eur J Gastroenterol Hepatol; 2024 May; 36(5):520-533. PubMed ID: 38477863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
    Archer R; Tappenden P; Ren S; Martyn-St James M; Harvey R; Basarir H; Stevens J; Carroll C; Cantrell A; Lobo A; Hoque S
    Health Technol Assess; 2016 May; 20(39):1-326. PubMed ID: 27220829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Network Meta-Analysis: Histologic and Histo-Endoscopic Improvement and Remission With Advanced Therapy in Ulcerative Colitis.
    Estevinho MM; Sousa-Pinto B; Moreira PL; Solitano V; Mesquita P; Costa C; Peyrin-Biroulet L; Danese S; Jairath V; Magro F
    Aliment Pharmacol Ther; 2024 Nov; 60(10):1276-1292. PubMed ID: 39367678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis.
    Sandborn WJ; Ghosh S; Panes J; Schreiber S; D'Haens G; Tanida S; Siffledeen J; Enejosa J; Zhou W; Othman AA; Huang B; Higgins PDR
    Gastroenterology; 2020 Jun; 158(8):2139-2149.e14. PubMed ID: 32092309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.